266 related articles for article (PubMed ID: 10765090)
21. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
22. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
23. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials.
Marberger MJ; Andersen JT; Nickel JC; Malice MP; Gabriel M; Pappas F; Meehan A; Stoner E; Waldstreicher J
Eur Urol; 2000 Nov; 38(5):563-8. PubMed ID: 11096237
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia.
Prieto L; Romero J; López C; Ortiz M; Pacheco JJ
Urol Int; 2008; 81(1):66-71. PubMed ID: 18645274
[TBL] [Abstract][Full Text] [Related]
25. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.
Albertsen PC; Pellissier JM; Lowe FC; Girman CJ; Roehrborn CG
Clin Ther; 1999 Jun; 21(6):1006-24. PubMed ID: 10440624
[TBL] [Abstract][Full Text] [Related]
26. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US-based insurance claims database.
Lee S; Yoo KH; Kim TS; Cho HJ; Kim W; Oh JK; Li S; Kim SY; Wei W; Huang J; van Uem S; Del Giudice F; Lindars DP; Sathe AR; Chung BI
Prostate; 2023 May; 83(7):722-728. PubMed ID: 36891865
[TBL] [Abstract][Full Text] [Related]
28. The natural history of benign prostatic hyperplasia.
Fitzpatrick JM
BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
[TBL] [Abstract][Full Text] [Related]
29. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
Magoha GA
East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
[TBL] [Abstract][Full Text] [Related]
30. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
31. Definition of at-risk patients: dynamic variables.
Emberton M
BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
[TBL] [Abstract][Full Text] [Related]
32. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
33. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
34. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Fenter TC; Davis EA; Shah MB; Lin PJ
Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
[TBL] [Abstract][Full Text] [Related]
35. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F; Adjali K; Gomez Guerra L; Hong SJ; El Khalid S; Ratana-Olarn K;
BJU Int; 2012 Jan; 109(1):88-95. PubMed ID: 22117624
[TBL] [Abstract][Full Text] [Related]
36. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
37. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.
Wilde MI; Goa KL
Drugs; 1999 Apr; 57(4):557-81. PubMed ID: 10235693
[TBL] [Abstract][Full Text] [Related]
38. Do alpha-blockers prevent the occurrence of acute urinary retention?
Hartung R
Eur Urol; 2001 Mar; 39 Suppl 6():13-8. PubMed ID: 11306896
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of medical treatment in benign prostatic hyperplasia.
Kim CI; Chang HS; Kim BK; Park CH
Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system.
Bahia LR; Araujo DV; Pepe C; Trindade M; Camargo CM; Javaroni V
Int Braz J Urol; 2012; 38(5):595-605. PubMed ID: 23131517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
